PROCF · Sofgen Pharma S.A.
Market Cap
$698,172
Shares
2.33B
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$373.8M
-11.8%
FY2024
Net Income
-$68.3M
-269.3%
FY2024
Gross Margin
51.23%
-4.9pp
FY2024
Operating Margin
-14.44%
-31.4pp
FY2024
Diluted EPS
-$0.68
-270%
FY2024
Operating Cash Flow
$88.43M
-17.8%
FY2024
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|
| $373.8M | $423.75M | $403.2M | $403.74M | $331.47M | $324.79M | |
| $182.32M | $185.77M | $168.08M | $173.67M | $140.15M | $142.29M | |
| $191.48M | $237.98M | $235.13M | $230.07M | $191.31M | $182.5M | |
| 51.23% | 56.16% | 58.32% | 56.99% | 57.72% | 56.19% | |
| $100.08M | $95.07M | $93.01M | $213.6K | $69.63M | $84.81M | |
| $122.97M | $98.28M | $643K | $3.63M | $3.78M | $60.26M | |
| -$53.99M | $72.08M | $9.81M | -$15.06M | — | — | |
| -14.44% | 17.01% | 2.43% | -3.73% | — | — | |
| — | — | — | $78.64M | $54.49M | $42.98M | |
| -$84.59M | $45.96M | $47.74M | -$93.9M | $849K | -$9.98M | |
| -$16.29M | $5.62M | $11.61M | $13.09M | $11.3M | $7.04M | |
| -$68.3M | $40.34M | $36.13M | -$106.99M | -$10.45M | -$17.01M | |
| -18.27% | 9.52% | 8.96% | -26.5% | -3.15% | -5.24% | |
| USD/shares | -$0.68 | $0.40 | $0.36 | -$1.09 | -$0.11 | -$0.18 |
| USD/shares | -$0.68 | $0.40 | $0.36 | -$1.09 | -$0.11 | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2021–FY2023: $45M in buybacks, $500K in dividends.